deltatrials
Terminated PHASE1 INTERVENTIONAL 4-arm NCT04332523

A Study of JNJ-53718678 in Participants With Hepatic Impairment

A Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Pharmacokinetics of JNJ-53718678

Sponsor: Janssen Research & Development, LLC

Conditions Hepatic Impairment
Interventions JNJ-53718678
Updated 18 times since 2020 Last updated: Jun 9, 2022 Started: Aug 17, 2020 Primary completion: Mar 16, 2022 Completion: Mar 16, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

A strategic decision was made to discontinue the study. The decision was not based on a safety concern.

Other terminated trials from Janssen Research & Development, LLC

More terminations from Janssen Research & Development, LLC

Other Hepatic Impairment trials with similar outcome

Browse all Hepatic Impairment trials

A PHASE1 clinical study on Hepatic Impairment, this trial is terminated or withdrawn. The trial is conducted by Janssen Research & Development, LLC and has accumulated 18 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Dec 2021 · 7 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 21 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jul 2022 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Recruiting → Terminated

  4. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  5. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

▶ Show 13 earlier versions

  1. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE1

  2. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE1

  3. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE1

  4. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  5. May 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  6. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE1

  7. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  8. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. Sep 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE1

  10. Aug 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE1

  11. Jul 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE1

  12. Jun 2020 — Jul 2020 [monthly]

    Not Yet Recruiting PHASE1

  13. May 2020 — Jun 2020 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Research & Development, LLC
Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations